Ekso Current Deferred Revenue vs Net Working Capital Analysis

EKSO Stock

USD 1.37 0.08 5.52%

Ekso Bionics financial indicator trend analysis is much more than just examining Ekso Bionics Holdings latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ekso Bionics Holdings is a good investment. Please check the relationship between Ekso Bionics Current Deferred Revenue and its Net Working Capital accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ekso Bionics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

Current Deferred Revenue vs Net Working Capital

Current Deferred Revenue vs Net Working Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ekso Bionics Holdings Current Deferred Revenue account and Net Working Capital. At this time, the significance of the direction appears to have very week relationship.

The correlation between Ekso Bionics' Current Deferred Revenue and Net Working Capital is 0.27. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Ekso Bionics Holdings, assuming nothing else is changed. The correlation between historical values of Ekso Bionics' Current Deferred Revenue and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Ekso Bionics Holdings are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Current Deferred Revenue i.e., Ekso Bionics' Current Deferred Revenue and Net Working Capital go up and down completely randomly.

Correlation Coefficient

0.27

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Net Working Capital

Most indicators from Ekso Bionics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ekso Bionics Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ekso Bionics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

As of the 17th of May 2024, Sales General And Administrative To Revenue is likely to grow to 1.01, while Selling General Administrative is likely to drop about 8.7 M.

	2021	2022	2023	2024 (projected)
Gross Profit	6.7M	6.2M	9.7M	5.1M
Total Revenue	11.2M	12.9M	18.3M	12.3M

Gross Profit Total Revenue

Ekso Bionics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Common Stock Total Equity	Non Current Liabilities Total	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Common Stock Shares Outstanding	Other Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt
Total Assets		0.53	0.75	0.83	0.9	-0.81	-0.74	0.93	0.92	0.33	0.61	0.77	0.99	0.38	0.37	0.44	0.81	-0.02	0.09	0.19	-0.55	0.74	0.16	-0.54	-0.56	0.36
Short Long Term Debt Total	0.53		0.76	0.69	0.33	-0.05	-0.75	0.32	0.31	-0.09	0.49	0.63	0.47	0.72	-0.06	0.44	0.76	-0.4	-0.28	0.53	-0.86	0.59	0.27	-0.87	-0.88	0.74
Other Current Liab	0.75	0.76		0.89	0.52	-0.44	-0.69	0.64	0.62	0.38	0.63	0.81	0.72	0.51	0.41	0.2	0.71	-0.17	-0.32	0.24	-0.73	0.71	0.03	-0.71	-0.73	0.54
Total Current Liabilities	0.83	0.69	0.89		0.56	-0.47	-0.8	0.65	0.63	0.52	0.7	0.9	0.78	0.68	0.56	0.31	0.82	0.01	-0.35	0.42	-0.63	0.83	0.21	-0.64	-0.66	0.39
Total Stockholder Equity	0.9	0.33	0.52	0.56		-0.84	-0.56	0.92	0.9	0.12	0.23	0.41	0.92	0.23	0.17	0.48	0.65	-0.25	0.48	0.03	-0.41	0.56	0.09	-0.4	-0.44	0.14
Net Debt	-0.81	-0.05	-0.44	-0.47	-0.84		0.29	-0.93	-0.96	-0.39	-0.34	-0.44	-0.87	0.05	-0.41	-0.05	-0.42	-0.19	-0.31	0.29	0.2	-0.44	0.2	0.18	0.15	-0.04
Retained Earnings	-0.74	-0.75	-0.69	-0.8	-0.56	0.29		-0.55	-0.49	-0.02	-0.6	-0.74	-0.7	-0.65	-0.07	-0.75	-0.98	0.23	0.19	-0.36	0.79	-0.75	-0.18	0.83	0.83	-0.62
Cash	0.93	0.32	0.64	0.65	0.92	-0.93	-0.55		0.99	0.31	0.48	0.6	0.97	0.15	0.34	0.27	0.63	0.02	0.22	-0.11	-0.46	0.62	-0.11	-0.43	-0.42	0.26
Cash And Short Term Investments	0.92	0.31	0.62	0.63	0.9	-0.96	-0.49	0.99		0.34	0.46	0.59	0.96	0.14	0.37	0.19	0.6	0.07	0.23	-0.14	-0.42	0.58	-0.12	-0.4	-0.38	0.24
Common Stock Total Equity	0.33	-0.09	0.38	0.52	0.12	-0.39	-0.02	0.31	0.34		0.39	0.49	0.31	0.22	1.0	-0.47	0.07	0.5	-0.39	0.07	0.14	0.18	-0.06	0.13	0.13	-0.28
Non Current Liabilities Total	0.61	0.49	0.63	0.7	0.23	-0.34	-0.6	0.48	0.46	0.39		0.94	0.55	0.21	0.41	0.13	0.59	0.52	-0.58	0.27	-0.4	0.55	0.18	-0.39	-0.35	0.59
Total Liab	0.77	0.63	0.81	0.9	0.41	-0.44	-0.74	0.6	0.59	0.49	0.94		0.71	0.46	0.52	0.22	0.75	0.32	-0.52	0.36	-0.54	0.73	0.21	-0.54	-0.52	0.54
Total Current Assets	0.99	0.47	0.72	0.78	0.92	-0.87	-0.7	0.97	0.96	0.31	0.55	0.71		0.32	0.35	0.39	0.77	-0.03	0.14	0.04	-0.56	0.71	0.01	-0.54	-0.55	0.34
Short Term Debt	0.38	0.72	0.51	0.68	0.23	0.05	-0.65	0.15	0.14	0.22	0.21	0.46	0.32		0.24	0.37	0.65	-0.34	-0.29	0.61	-0.64	0.59	0.24	-0.68	-0.71	0.24
Common Stock	0.37	-0.06	0.41	0.56	0.17	-0.41	-0.07	0.34	0.37	1.0	0.41	0.52	0.35	0.24		-0.42	0.11	0.48	-0.38	0.1	0.12	0.22	-0.03	0.11	0.1	-0.27
Common Stock Shares Outstanding	0.44	0.44	0.2	0.31	0.48	-0.05	-0.75	0.27	0.19	-0.47	0.13	0.22	0.39	0.37	-0.42		0.7	-0.46	0.28	0.33	-0.48	0.48	0.37	-0.52	-0.58	0.34
Other Stockholder Equity	0.81	0.76	0.71	0.82	0.65	-0.42	-0.98	0.63	0.6	0.07	0.59	0.75	0.77	0.65	0.11	0.7		-0.2	-0.12	0.33	-0.78	0.77	0.17	-0.83	-0.82	0.59
Other Liab	-0.02	-0.4	-0.17	0.01	-0.25	-0.19	0.23	0.02	0.07	0.5	0.52	0.32	-0.03	-0.34	0.48	-0.46	-0.2		-0.44	-0.14	0.43	-0.03	-0.04	0.44	0.52	-0.13
Net Tangible Assets	0.09	-0.28	-0.32	-0.35	0.48	-0.31	0.19	0.22	0.23	-0.39	-0.58	-0.52	0.14	-0.29	-0.38	0.28	-0.12	-0.44		-0.29	0.25	-0.19	0.04	0.22	0.15	-0.37
Property Plant And Equipment Net	0.19	0.53	0.24	0.42	0.03	0.29	-0.36	-0.11	-0.14	0.07	0.27	0.36	0.04	0.61	0.1	0.33	0.33	-0.14	-0.29		-0.2	0.32	0.84	-0.21	-0.29	0.12
Current Deferred Revenue	-0.55	-0.86	-0.73	-0.63	-0.41	0.2	0.79	-0.46	-0.42	0.14	-0.4	-0.54	-0.56	-0.64	0.12	-0.48	-0.78	0.43	0.25	-0.2		-0.66	0.15	0.99	0.96	-0.71
Accounts Payable	0.74	0.59	0.71	0.83	0.56	-0.44	-0.75	0.62	0.58	0.18	0.55	0.73	0.71	0.59	0.22	0.48	0.77	-0.03	-0.19	0.32	-0.66		0.15	-0.63	-0.66	0.32
Non Current Assets Total	0.16	0.27	0.03	0.21	0.09	0.2	-0.18	-0.11	-0.12	-0.06	0.18	0.21	0.01	0.24	-0.03	0.37	0.17	-0.04	0.04	0.84	0.15	0.15		0.13	0.03	-0.03
Non Currrent Assets Other	-0.54	-0.87	-0.71	-0.64	-0.4	0.18	0.83	-0.43	-0.4	0.13	-0.39	-0.54	-0.54	-0.68	0.11	-0.52	-0.83	0.44	0.22	-0.21	0.99	-0.63	0.13		0.98	-0.71
Other Assets	-0.56	-0.88	-0.73	-0.66	-0.44	0.15	0.83	-0.42	-0.38	0.13	-0.35	-0.52	-0.55	-0.71	0.1	-0.58	-0.82	0.52	0.15	-0.29	0.96	-0.66	0.03	0.98		-0.61
Long Term Debt	0.36	0.74	0.54	0.39	0.14	-0.04	-0.62	0.26	0.24	-0.28	0.59	0.54	0.34	0.24	-0.27	0.34	0.59	-0.13	-0.37	0.12	-0.71	0.32	-0.03	-0.71	-0.61

Click cells to compare fundamentals

Ekso Bionics Account Relationship Matchups

Ekso Bionics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	21.9M	20.6M	49.2M	40.9M	28.9M	26.0M
Short Long Term Debt Total	3.9M	3.9M	2.2M	7.5M	7.2M	3.7M
Other Current Liab	1.7M	1.4M	2.3M	2.3M	2.7M	2.3M
Total Current Liabilities	7.8M	5.0M	6.9M	9.2M	8.1M	6.6M
Total Stockholder Equity	6.8M	4.4M	37.2M	25.4M	12.6M	13.6M
Net Debt	(7M)	(9.0M)	(38.2M)	(13.0M)	(1.5M)	(1.5M)
Retained Earnings	(183.3M)	(199.1M)	(208.9M)	(223.9M)	(239.1M)	(227.2M)
Cash	10.9M	12.9M	40.4M	20.5M	8.6M	16.1M
Cash And Short Term Investments	10.9M	12.9M	40.4M	20.5M	8.6M	8.2M
Common Stock Total Equity	60K	63K	87K	8K	9.2K	8.7K
Liabilities And Stockholders Equity	21.9M	20.6M	49.2M	40.9M	28.9M	26.0M
Non Current Liabilities Total	7.3M	11.2M	5.1M	6.3M	8.2M	7.4M
Total Liab	15.1M	16.2M	11.9M	15.5M	16.3M	13.4M
Total Current Assets	18.8M	18.4M	47.8M	31.0M	20.2M	22.1M
Short Term Debt	2.8M	548K	229K	2.7M	1.6M	1.1M
Common Stock	63K	87K	8K	13K	15K	14.3K
Common Stock Shares Outstanding	4.8M	7.2M	12.3M	13.0M	13.9M	14.6M
Other Stockholder Equity	189.9M	204.4M	246.1M	248.8M	251.6M	179.6M
Other Liab	6.2M	7.9M	3.1M	1.4M	1.3M	1.2M
Net Tangible Assets	6.6M	4.4M	37.2M	19.8M	22.8M	15.5M
Property Plant And Equipment Net	2.7M	1.9M	1.2M	4.0M	3.0M	2.7M
Current Deferred Revenue	1.5M	1.5M	1.2M	1.1M	2.0M	1.4M
Accounts Payable	1.9M	1.5M	3.1M	3.2M	1.8M	2.5M
Non Current Assets Total	3.1M	2.2M	1.4M	9.9M	8.7M	5.0M
Non Currrent Assets Other	178K	320K	164K	231K	392K	504.2K
Other Assets	134K	178K	1.0M	164K	147.6K	140.2K
Long Term Debt	407K	9.1M	2.0M	3.8M	4.8M	3.8M
Net Receivables	5.2M	3.4M	4.7M	4.6M	5.6M	3.9M
Long Term Debt Total	4.8M	2.6M	407K	9.1M	10.5M	11.0M
Capital Surpluse	165.8M	173.9M	189.9M	204.4M	235.0M	165.0M
Inventory	2.5M	2.0M	2.2M	5.2M	5.1M	2.9M
Other Current Assets	238K	191K	485K	700K	875K	597.9K
Property Plant And Equipment Gross	2.7M	1.9M	1.2M	4.0M	6.2M	6.5M
Accumulated Other Comprehensive Income	50K	(847K)	(17K)	563K	156K	163.8K
Property Plant Equipment	2.7M	1.2M	1.2M	4.0M	4.6M	2.6M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Ekso Bionics Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ekso Bionics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ekso Bionics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ekso Bionics Holdings Stock:

How To Invest In Ekso

Details

Is Ekso Stock a good investment?

Details

What is Ekso Bionics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ekso Bionics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Ekso Stock analysis

When running Ekso Bionics' price analysis, check to measure Ekso Bionics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ekso Bionics is operating at the current time. Most of Ekso Bionics' value examination focuses on studying past and present price action to predict the probability of Ekso Bionics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ekso Bionics' price. Additionally, you may evaluate how the addition of Ekso Bionics to your portfolios can decrease your overall portfolio volatility.

	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities

Is Ekso Bionics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ekso Bionics. If investors know Ekso will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ekso Bionics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.97)

Revenue Per Share

1.202

Quarterly Revenue Growth

(0.09)

Return On Assets

(0.26)

Return On Equity

(0.81)

The market value of Ekso Bionics Holdings is measured differently than its book value, which is the value of Ekso that is recorded on the company's balance sheet. Investors also form their own opinion of Ekso Bionics' value that differs from its market value or its book value, called intrinsic value, which is Ekso Bionics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ekso Bionics' market value can be influenced by many factors that don't directly affect Ekso Bionics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ekso Bionics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ekso Bionics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ekso Bionics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ekso Current Deferred Revenue vs Net Working Capital Analysis

Current Deferred Revenue vs Net Working Capital

Current Deferred Revenue vs Net Working Capital Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Net Working Capital

Ekso Bionics fundamental ratios Correlations

Ekso Bionics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ekso Bionics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Ekso Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Total Current Assets	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Cash
Non Currrent Assets Other	+ 0.99	Current Deferred Revenue
Other Assets	+ 0.98	Non Currrent Assets Other
Total Current Assets	+ 0.97	Cash

Other Stockholder Equity	- 0.98	Retained Earnings
Cash And Short Term Investments	- 0.96	Net Debt
Cash	- 0.93	Net Debt
Other Assets	- 0.88	Short Long Term Debt Total
Total Current Assets	- 0.87	Net Debt
Non Currrent Assets Other	- 0.87	Short Long Term Debt Total